Split Decision: Synthego Spins Out EditCo Bio Around Engineered Cell Platform
Synthego announced that it will focus solely on the therapeutic applications of CRISPR while spinning off a new company, EditCo Bio, which is positioned to deliver edited cells and highly optimized guide RNA designs for customer needs across both basic research and preclinical phases of CRISPR-based therapy.